Results from a Phase 1 study indicate that tabalumab in combination with Velcade demonstrates both efficacy and safety in myeloma patients who have relapsed after several previous therapies.

Dr. Nooper Raje from Massachusetts General Hospital in Boston presented the results of the study at the American Society of Hematology (ASH) annual meeting earlier this month. She explained that tabalumab was very promising in this particular patient population, and added that “this was a very well tolerated regimen.”

However, Dr. Raje emphasized that further study of tabalumab at higher doses and in combination …

This year’s meeting of the American Society of He­ma­tol­ogy (ASH) was held De­cem­ber 8 through 11 in Atlanta.

During the meeting, The Beacon pub­lished daily up­dates that provided overviews of the im­por­tant mul­ti­ple myeloma findings pre­sented during the meeting.  After the meeting concluded, The Beacon began pub­lishing in-depth articles about the key re­search findings.

This article, how­ever, shifts the focus to the bigger picture: What were the key findings of the meeting? Were there re­­sults with im­medi­ate implica­tions for the treat­ment of mul­ti­ple myeloma?  Did the re­search …

Results from a Phase 1/2 study show that dinaciclib has anti-myeloma activity in relapsed multiple myeloma patients.

“The current study shows encouraging potential for the single-agent [use of dinaciclib] in patients with relapsed multiple myeloma,” said Dr. Shaji Kumar from the Mayo Clinic, who presented the results at the American Society of Hematology (ASH) meeting last week. He added that the treatment was also “well-tolerated with toxicity that was manageable.”

However, Dr. Kumar explained that further studies are needed to determine an optimal dosing schedule and to evaluate dinaciclib in combination with …

Results from three Chinese clinical trials indicate that the investigational drug circularly permuted TRAIL may be effective alone or in combination with thalidomide in relapsed and refractory multiple myeloma patients.

However, further testing of the drug is necessary to determine its optimal dose.

Dr. Wenming Chen from the Chaoyang Hospital of Capital Medical University in Beijing presented the findings from the three studies last week at the American Society of Hematology (ASH) annual meeting in Atlanta.

Circularly Permuted TRAIL (CPT) is being developed by Beijing Sunbio Biotech as a treatment for multiple …

ARRY-520 is one of several potential new anti-myeloma agents that was highlighted at the American Society of Hematology (ASH) annual meeting earlier this week.

Initial results from two clinical trials show promise for ARRY-520 (filanesib), alone or in com­bi­na­tion with other myeloma drugs, as a thera­peutic option for heavily pretreated multiple myeloma patients.

“ARRY-520 shows promising activity in com­bi­na­tion with dexa­meth­a­sone in heavily pretreated myeloma patients,” said Dr. Jatin Shah, from the MD Anderson Cancer Center in Houston and lead investigator of both studies.

Based on their findings, the study investigators …

Tuesday was the final day of this year’s American Society of Hematology (ASH) meeting, which took place in Atlanta.  The meeting concluded in the morning with a series of oral presentation sessions held simultaneously.

Three of the morning sessions focused on the biology of multiple myeloma as well as preclinical and clinical studies of treat­ment options for multiple myeloma patients.

This update will summarize the research presented during the session that focused on myeloma treat­ment options.  In addi­tion, it will summarize results from an important late-breaking study of poma­lido­mide that also was …

Monday was the third and next-to-last day of the 2012 American Society of Hematology (ASH) annual meeting.

It also was the busiest day of the meeting in regard to myeloma-related research.

The day ended with a poster session in the evening that featured over 1000 posters displayed throughout a large conference hall.  More than a hundred of the posters reported on the results of myeloma-related research.

Compared to the research summarized during oral presentations, the findings in poster summaries generally are in earlier stages of development.  They may involve laboratory research, clinical …